Biomedical engineering & implants

Biomedical engineering & implants is the design and manufacture of devices that interact structurally or electrically with the human body — titanium joint prostheses, cardiovascular stents and valves, cardiac pacemakers and defibrillators, neurointerfaces and tissue-engineered biomaterials. It is the highest-value segment of medical technology: Stryker alone reported $11.2 billion in orthopedic sales for 2025, up 4.7% year on year, and Siemens Healthineers reached €23.4 billion in FY25 revenue with €12.1 billion from imaging. The field is bifurcating along two axes — precision and cost. On the precision axis, robotic-assisted arthroplasty and 3D-printed personalized implants command a large innovation premium (a Mako robotic system is a roughly $1 million capital purchase and over a million Stryker robotic procedures have been performed). On the cost axis, China’s Volume-Based Procurement (VBP) tenders collapsed the price of a coronary stent from about 13,000 yuan to roughly 700 yuan, shifting volume to domestic manufacturers. Underneath both axes, every implant is gated by a device regulator — FDA 510(k)/PMA in the US, the EU Medical Device Regulation (MDR 2017/745) with notified-body certification and UDI traceability in Europe, and NMPA registration in China.

The key directions of biomedical engineering & implants are:

1. Orthopedic and dental implants (titanium, bio-ceramics, 3D-printed): cementless joint prostheses, hydroxyapatite bone scaffolds and lattice-optimized 3D-printed implants placed under robotic control for osseointegration.
2. Cardiovascular implants (stents, TAVR valves, pacemakers): drug-eluting coronary stents, transcatheter aortic valve replacement (TAVR) systems and connected defibrillators delivered minimally invasively.
3. Neurointerfaces and brain–computer interfaces (BCI): surgically implanted electrode arrays and wireless implants that decode motor or sensory signals for paralysis, blindness and neuromotor disorders.
4. Tissue-engineered biomaterials: medical-grade hyaluronic acid, collagen matrices and cell-seeded engineered skin for wound healing, dermal reconstruction and drug delivery.

Sectoral value chain#

[Biocompatible materials] ──> [Imaging & AI design] ──> [Manufacturing (CNC / SLM)]
                                       │
                              (porous lattice, osseointegration)
                                       │
                                       ▼
[Surgical implantation] <─── [Sterilization & QMS] <─── [Regulatory clearance]

Value chain levels#

Cross-cutting technologies of the sector:

• Surgical robotics: haptic-boundary robotic arms (Stryker Mako) that map the patient’s bone in 3D and constrain the cutter to the planned implant envelope, raising placement precision.
• Connected implants: pacemakers and ICDs with Bluetooth telemetry (e.g. Abbott Gallant) that stream device status to a clinician app, turning the implant into a monitoring node.
• 3D-printed porous lattices: patient-specific implants with computationally graded porosity that mimics trabecular bone, manufactured by selective laser melting for complex oncology and revision cases.

The biomedical-implant stack joins an implantable hardware core, an imaging-and-robotics delivery layer and a regulatory-quality substrate into one device ecosystem.

1. Robotic-assisted surgery and 3D-printed personalized implants:
   • Haptic-boundary robotic arms (Stryker Mako) build a 3D model of the patient’s bone from CT and constrain the surgeon’s tools to a planned envelope, with Mako Shoulder reaching full market release in 2026 and the handheld Mako RPS entering limited release in February 2026.
   • Zimmer Biomet’s Persona SoluTion and G7 hip systems and 3D-printed metamaterial femoral prostheses use selective laser melting to grade implant porosity for osseointegration, certified under FDA 510(k) clearance.
2. Minimally invasive cardiovascular implants:
   • Transcatheter aortic valve replacement (Medtronic Evolut FX+) is delivered over a catheter and won FDA approval for Redo-TAVR (valve-in-valve) in August 2025 plus a CE Mark for redo-TAVI.
   • Drug-eluting coronary stents (MicroPort FireT, Lepu) deliver antiproliferative drugs from polymer coatings, and connected ICDs (Abbott Gallant) stream status over Bluetooth to a clinician app.
3. Neurointerfaces and connected implants:
   • Invasive BCI implants (Neuralink N1) use a surgical robot (R1) to thread micro-electrode filaments into the motor cortex and transmit decoded neural signals wirelessly, with five therapeutic programs running across four countries.
   • Connected implant telemetry turns pacemakers and ICDs into continuous monitoring nodes, and EU MDR UDI labelling makes every device traceable through EUDAMED.